MedPath

Maintenance rTMS for Treatment-resistant Depression (TRD): a One-year Double Blind Controlled Study

Phase 2
Conditions
Major Depressive Disorder
Interventions
Device: Repetitive Transcranial Magnetic Stimulation
Registration Number
NCT02383693
Lead Sponsor
Centre hospitalier de Ville-Evrard, France
Brief Summary

number of center : 1

* duration of study : 24 months

* recruitement time : 23 months

* Aim :Principal

Evaluate the interest of maintenance rTMS in a one-year double blind randomized controlled study for TRD patients.

Secondary

Evaluate the impact of rTMS on cognitive functions.

Detailed Description

The study involves 40 TRD patients in a single site trial which consisted of two phases: an acute phase (phase I) in which all the participants receive active high-frequency stimulation during 4 blocks of five consecutive working days (Monday to Friday) in an open-label design and a maintenance phase (phase II) in which responders (\> 49% HDRS-17 reduction from baseline) at the end of the phase I are randomized in two arms with sham or active high-frequency rTMS maintenance treatment for the eleven following months. The rhythm of rTMS sessions in this maintenance phase is gradually reduced as follows: 3 sessions per week for 2 weeks, 2 session per week for the 2 following weeks, 1 session per week the third (M3) and fourth month (M4) and then 1 session every fortnight the last eight months (M5 to M12).

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
40
Inclusion Criteria
  • TRD stage I Thase-Rush
  • HDRS + or = 18
  • Patients age 18 to 70 years.
  • Negative pregnancy test and contraception for women.
  • Informed Consent
Exclusion Criteria
  • Patient was treated with mood stabilizer in the previous week
  • Other disorder on axis I of the DSM IV than depressive disorder.
  • Patient with an addiction problem other than tobacco and caféine
  • antécedent of Epilepsy ,other neurological pathology and intra cranial metal diapositive or pacemaker
  • Previous history of head trauma the previous two years.
  • intracranial hypertension.
  • not affiliated to the social security Patient
  • patient under constraint hospitalisation
  • Under legal protection measure

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
repetitive transcranial magnetic stimulationRepetitive Transcranial Magnetic StimulationRepetitive Transcranial Magnetic Stimulation (rTMS) Treatment 5 days/week for up to 4 weeks
Sham comparatorRepetitive Transcranial Magnetic StimulationPlacebo Comparator: Placebo Treatment 5 days/week for up to 4 weeks
Primary Outcome Measures
NameTimeMethod
'Hamilton depression rating scale (HDRS)one years

The efficacy variables included the HDRS-17 item scores, the CGI changes, the Visual Analog Scale (VAS), the Beck Depression Inventory (BDI) and the Hospital Anxiety Depression (HAD).

The subjective assessment performed with the VAS consisted of a 100-mm horizontal line oriented with anchors placed at both poles for reassured, sadness, anxiety, and relief. The patients are asked to mark a spot along this line that best indicated the magnitude of their state for each item.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Unité de Recherche Clinique

🇫🇷

Neuilly Sur Marne, Île de France, France

© Copyright 2025. All Rights Reserved by MedPath